Revvity Inc. RVTY

Revvity, Inc. launched the GSP T1D 3plex kit in Europe, a CE-IVDR-certified, fully automated multiplex autoantibody detection solution for population-wide screening of children at risk of type 1 diabetes (T1D) before symptoms appear. The assay uses capillary dried blood spot samples and runs on Revvity's GSP instrument, extending its newborn-screening capabilities into early childhood. Initially available in Europe and other CE-marked markets; FDA clearance is still pending. The kit targets autoantibodies GAD, IA-2, and ZnT8, enabling detection of individuals at risk prior to clinical onset and supporting emerging national screening initiatives. Revvity emphasizes regulatory compliance and scalability, arguing the GSP T1D 3plex complements its diabetes portfolio and the company's automated, high-throughput workflows. Management views the launch as a key step in expanding child health screening, with potential uptake by screening programs seeking scalable, DBS-based testing. Expands a CE-marked, automated T1D screening capability into Europe, potentially broadening the addressable market and strengthening growth, though FDA clearance remains pending.

Revvity launches the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution for population-wide screening to identify children at risk of type 1 diabetes before symptoms. The assay uses capillary dried blood spots collected through a DBS-based newborn screening workflow and runs on Revvity’s GSP instrument, delivering a high-throughput, end-to-end workflow with reagents, instrumentation, and software. The kit aims to detect at-risk individuals months or years before onset, enabling early intervention and potential disease-modifying treatment. It expands Revvity’s diagnostic offerings from newborn screening into early childhood screening. It will initially be available in Europe and other CE IVD-marked markets, not FDA-cleared in the U.S. Revvity highlights collaboration with Sanofi on on-site installation and off-site testing services, and will present details at EASD in Milan. Revenue size noted: 2025 revenue around $2.9B and ~11,000 employees. Introduces a CE-IVDR-certified, automated T1D screening workflow with DBS samples and Sanofi collaboration, expanding addressable markets and growth potential, though U.S. clearance remains pending.

Revvity, Inc. (RVTY) is a $16B Waltham, MA-based health-sciences leader in translational multi-omics, biomarker discovery, imaging, and diagnostics, offering reagents, assay kits, and imaging solutions. With 160+ countries and about 2,000 sales reps, it leverages AI-enabled life sciences and a broad, diversified portfolio. The stock has momentum, rising about 45% in 3 months and 66% over the last year, and has traded above its 50- and 200-day moving averages since May. Diagnostics strength and accelerating AI demand have boosted orders for Opera Phenix OptIQ, raising backlog and signaling future reagent demand. It exited its China immunodiagnostics business and reinvested tariff refunds into capacity and R&D, guiding to better end-markets and AI adoption. Analysts show a bullish stance (consensus Moderate Buy) with a mean target around 128.59 and a street-high near 165. AI-driven demand, backlog growth, and capacity expansion with higher guidance could materially improve Revvity's trajectory.

Revvity Inc. (RVTY) has gained attention after shares rallied, up about 15% in the last month and roughly 36% in the last three months. Over the past year, the stock rebounded from underwhelming five-year performance, with a 5-year TSR of -16.56% but a 1-year TSR of 67.67% and a 90-day price return of 35.67%. The company posted revenue of about $2.9 billion and net income of $237.4 million. The stock closed at $143.31 while Simply Wall St’s fair value estimate sits at $126.12, signaling the stock may be overvalued by around 14%. Analysts expect a shift in product mix toward higher-margin software-enabled offerings and consumables (e.g., SaaS Signals, reagents, IDS i20 platform) along with cost actions to lift operating and net margins, targeting a higher 28% operating margin baseline by 2026. Risks include weaker academic/government spending and potential pricing or regulatory pressures in key diagnostics markets. Valuation appears stretched despite potential margin expansion from software-enabled offerings.

Revvity Inc. (RVTY) announced acquisition of Human Cell Design to strengthen metabolic discovery capabilities. Acquisition adds targeted metabolic research tools with moderate effects on innovation and positioning.

Revvity acquires Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery. Acquisition represents a major strategic move to expand Revvity's cell modeling capabilities for drug discovery.

Revvity Inc. reports improving growth while its valuation remains elevated, prompting questions on whether the stock qualifies as a buy. Growth improvement and valuation concerns can moderately shift investor views on Revvity's near-term performance.

Revvity (RVTY) encounters a valuation test on its margins story after receiving a Zacks upgrade. Zacks upgrade places Revvity margins under valuation scrutiny that may shift investor sentiment without changing core operations.

Revvity Inc. faces growth challenges amid rising competition, according to RBC. Rising competition creates growth hurdles that may moderately pressure Revvity's financial performance and market position.

Revvity launches SuperFlex prenatal screening system for smaller labs. SuperFlex launch targets smaller labs to expand prenatal screening access.

Revvity Inc. addressed five key analyst questions during its Q2 earnings call, covering financial results, operational updates, and forward-looking guidance on core business segments. Q2 earnings call details and analyst questions can shape short-term investor views on Revvity's financial trajectory without indicating major strategic shifts.

Revvity (RVTY) held its Q2 2026 earnings call, covering financial results, operational updates, and forward guidance. Quarterly earnings call delivers financial results and guidance that directly shape near-term stock valuation and investor outlook.

Revvity Inc. launches SuperFlex Prenatal Screening System to expand access to preeclampsia testing. New product launch in prenatal screening may improve Revvity market position and diagnostics revenue.

Revvity Inc. (RVTY) presented highlights from its Q2 earnings call covering financial results and future outlook. Q2 earnings call updates on performance and guidance can shift near-term investor sentiment without altering long-term trajectory.

Revvity beat Q2 earnings, raised full-year guidance, and exited China operations, prompting questions on whether these moves change the bull case for the stock. Q2 beat, raised guidance, and China exit represent major financial outperformance plus strategic shift likely to alter company trajectory and investor views.

Revvity Inc. beat Q2 earnings estimates on diagnostics strength and raised its 2026 outlook. Q2 earnings beat and raised 2026 guidance point to stronger financial results and improved future prospects.

Revvity Inc reported strong diagnostics growth in its Q2 2026 earnings call and raised its financial outlook. Strong diagnostics growth and raised outlook point to improved revenue trajectory and investor sentiment.

Revvity Inc. beat second-quarter estimates and raised its full-year outlook. Beating estimates combined with raised guidance signals stronger performance and lifts investor sentiment.

Revvity Inc. released financial results for the second quarter of 2026. Quarterly results typically drive immediate shifts in valuation and investor outlook.

Revvity Inc. discussed Q2 2026 financial results, performance metrics, and future outlook during its earnings call. Quarterly earnings calls deliver financial updates and guidance that moderately influence near-term market sentiment and valuation.

Revvity Inc. (RVTY) reported Q2 earnings and revenues that exceeded analyst estimates. Q2 earnings and revenue beat supports near-term gains in investor sentiment and stock performance.

Revvity Inc. reported upbeat Q2 CY2026 earnings. Upbeat quarterly results can lift near-term stock sentiment and financial outlook.

Revvity (RVTY) is scheduled to report earnings tomorrow. Earnings releases can moderately move stock prices and investor views.

Avantor shares rose after one business segment stopped contracting, signaling potential stabilization in that area of operations. Stabilization in a single segment offers moderate positive signal but does not indicate broad operational turnaround.

Revvity Inc. is scheduled to report its Q2 earnings, with focus on anticipated results and potential effects on the company's stock performance. Upcoming earnings release may affect short-term stock sentiment and valuation but represents a routine event unlikely to fundamentally reshape long-term company trajectory.

Revvity (RVTY) earnings are projected to grow in the upcoming quarterly release next week. Earnings growth expectations can moderately influence near-term investor sentiment and stock trajectory for Revvity.

Revvity develops high-throughput T-SPOT.TB platform for clinical labs. New high-throughput T-SPOT.TB platform launch may improve Revvity's diagnostic offerings and lab market reach.

Revvity Inc. will launch Signals for Startups program aimed at emerging biotech companies. New program launch targets biotech startups and may improve positioning and partnerships without major near-term financial shifts.

Revvity launches Signals for Startups program to assist emerging biotechs in establishing scalable digital foundations immediately. Launch of Signals for Startups targets emerging biotechs for long-term platform adoption.

Alamar achieves record performance amid surging interest in Alzheimer's research tied to Revvity Inc. (RVTY) tools and platforms. Alzheimer's buzz around Alamar offers moderate visibility gains but lacks concrete financial or regulatory triggers for Revvity.